Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. SMR 2017, abstract FC05-3.
Neoadjuvant dostarlimab bij mismatch repair-deficiënte tumoren
jul 2025 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie, Uro-oncologie